Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colorectal Neoplasms 86Colonic Neoplasms 32Rectal Neoplasms 31Neoplasms 24Pancreatic Neoplasms 22Stomach Neoplasms 20Neoplasm Metastasis 20Esophageal Neoplasms 20Neuroblastoma 12Glioma 11Sarcoma 9Glioblastoma 9Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Adenocarcinoma Of Esophagus 8Rhabdomyosarcoma 7Lung Neoplasms 7Sarcoma, Ewing 6Gliosarcoma 6Esophageal Squamous Cell Carcinoma 6Medulloblastoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Digestive System Diseases 4Adenocarcinoma 4

Interventions

Bevacizumab 3Temozolomide 2Sorafenib 2pembrolizumab 1Valproic Acid 1Therapeutics 1Sildenafil Citrate 1Radiosurgery 1Irinotecan 1Equipment and Supplies 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurologic Manifestations × Irinotecan × Clear all
NCT00360828 2017-03-23

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
10 enrolled 6 charts
CNS

Astrocytoma, Brain Neoplasms, Glioma, Neurologic Manifestations, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡